此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC (QUATTRO)

2017年6月15日 更新者:EPS Corporation

A Multicenter, Clinical Phase II Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With Metastatic Colorectal Cancer

The purpose of this study to assess efficacy and tolerability of combination therapy FOLFOXIRI with Bevacizumab (BV) as a first-line therapy in patients with metastatic colorectal cancer.

研究概览

详细说明

This is a single-arm, multicentre phase II study evaluating the efficacy and safety of Bevacizumab (BV) in combination with oxaliplatin, irinotecan hydrochloride, fluorouracil, and leucovorin calcium regimen ( FOLFOXIRI +BV ; Falcone et al. ASCO2013) as first-line treatment for Japanese metastatic colorectal cancer patients.

This study is composed two steps because of collecting safety issue in Japanese patient.

As First step (Step 1), It assess on the initial safety information in ten Japanese patients of the end of 2nd cycle. it is evaluated by DMC.

In parallel with the confirmation of the initial safety issue, register up to 65 cases in total and Step 1 patient, to evaluate the efficacy and safety (Step2).

研究类型

介入性

注册 (实际的)

69

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Tokyo
      • Shinjuku、Tokyo、日本、162-0814
        • EPS Corporation

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Written Informed consent.
  2. Histopathologically proven diagnosis of colorectal cancer (adenocarcinoma) excluding vermiform appendix cancer and proctos cancer.
  3. Not resectable metastatic colorectal cancer
  4. Age at enrollment is >= 20 and <= 75 years
  5. ECOG PS < 2 if age < 70 years, ECOG PS = 0 if age = 71-75 years
  6. One or more measurable lesion in RECIST ver.1.1 criteria according to contrast enhanced CT chest / abdomen / pelvis diagnosis.
  7. Not previously treated with chemotherapy. ( Previous adjuvant by fluoropyrimidine monotherapy is allowed if more than 24 weeks have elapsed between the end of adjuvant therapy and first relapse.)
  8. Vital organ functions (listed below) are preserved within 2 weeks prior to entry. Data recorded nearest to the entry should be referred. Blood transfusion or erythropoiesis stimulating agents less than 2 weeks prior to the tests are not allowed.

    Neu. >= 1,500/cubicmillimeter Pt. >= 100,000/cubicmillimeter Hb. >= 9.0 g/dL T-bil. <= upper limit of normal (ULN)*1.5 AST and ALT,ALP <= upper limit of normal (ULN)*2.5 (<= ULN*5 in case of liver metastasis) Serum creatinine <= upper limit of normal (ULN) *1.5 PT-INR < 1.5 Proteinuria <= 2+

  9. UGT1A1 genotype tested. Categorized into Wild or single Hetero.

Exclusion Criteria:

  1. Previously treated with irradiation to bone marrow constituting 20% or more of irradiation field.
  2. Untreated brain metastases or spinal cord compression or primary brain tumors.
  3. History of CNS disease.[except for asymptomatic Lacunar stroke]
  4. Requiring chronic systemic corticosteroid treatment.
  5. Current or recent ongoing treatment with anticoagulants.
  6. Clinically significant cardiovascular disease for example cerebrovascular accidents, myocardial infarction, unstable angina, congestive heart failure, serious cardiac arrhythmia requiring medication.
  7. Treatment with any investigational drug within 4 weeks.
  8. Patient with Uncontrolled hypertension, Uncontrolled diabetes, Uncontrolled diarrhea, >=grade 1 peripheral neuropathy, Active peptic ulcer, Non-healing wound, Clinically important diseases.
  9. Major surgical procedure within 28 days prior to study treatment start, open biopsy, or significant traumatic injury, or anticipation of the need for major surgical procedure.[except for implantation of central venous catheter and port system.]
  10. Lack of physical integrity of the upper gastrointestinal tract.
  11. Pregnant women, lactating woman , positive by pregnancy test , wishing to become pregnant, and Sexually active males.
  12. Hepatitis B or hepatitis C. Evidence of HIV infection.
  13. Previous Chemotherapy for other organs.
  14. Other active co-existing malignancies.
  15. History / Presence of thrombosis within 1 year requiring medication.
  16. History / Presence of paralytic ileus, obstruction or gastrointestinal perforation.
  17. Malignant coelomic fluid required drainage.
  18. History of allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications.
  19. History of fluoropyrimidine severe side effects caused by DPD defect.
  20. Interstitial pneumonitis or pulmonary fibrosis.
  21. Evidence or requiring systemic treatment for Infectious disease.
  22. Patient who is judged by the investigator to be inappropriate for study participation for any reason.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:FOLFOXIRI plus bevacizumab

Induction therapy is followed by the maintenance therapy.

[Induction treatment:FOLFOXIRI plus bevacizumab] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.

[Maintenance treatment:5-FU / I-LV plus bevacizumab] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.

鉴于IV
其他名称:
  • BV
鉴于IV
其他名称:
  • L-OHP
鉴于IV
其他名称:
  • 5-氟尿嘧啶
鉴于IV
其他名称:
  • CPT-11
鉴于IV
其他名称:
  • 低压

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-free survival (PFS) at 10 months
大体时间:PFS rate at 10 months from study entry

PFS by investigator-reported measurements according to CT image. PFS was calculated from the day of treatment start to the first observation of progression disease (PD) or death from any cause.

PD was defined as Overall Response by RECIST criteria v1.1 according to CT image.

PFS rate at 10 months from study entry

次要结果测量

结果测量
措施说明
大体时间
Response rate (RR) by central review.
大体时间:Up to 18 months
Response evaluation was performed according to RECIST criteria v1.1.
Up to 18 months
Response rate (RR) by investigator-reported measurements.
大体时间:Up to 30 months
Response evaluation was performed according to RECIST criteria v1.1.
Up to 30 months
PFS by central review according to CT image.
大体时间:Up to 18 months
PFS was calculated from the day of treatment start to the first observation of progression disease (PD) or death from any cause.
Up to 18 months
Overall survival (OS)
大体时间:Up to 30 months
OS was calculated from the day of registration in this study to death from any cause.
Up to 30 months
Efficacy by RAS status ; RR,PFS,OS
大体时间:Up to 30 months
RR,PFS,OS according to tumor RAS status.
Up to 30 months
Incidence of adverse events
大体时间:Up to 30 months
Adverse events were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0. All adverse events was collected in duration from starting treatment to whichever shorter "after 30 days from withdrawal treatment" or "later treatment was started".
Up to 30 months
Time to treatment-failure
大体时间:Up to 30 months
Up to 30 months
Completion rate in Induction treatment
大体时间:Up to 30 months
Up to 30 months
Relative Dose Intensity
大体时间:Up to 30 months
Up to 30 months
Treatment duration
大体时间:Up to 30 months
Up to 30 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Takeshi Kato, M.D., Ph.D、Department of Surgery, National Hospital Organization Osaka National Hospital.
  • 首席研究员:Akiyoshi Kanazawa, M.D., Ph.D、Department of Surgery, Shimane Prefectural Central Hospital.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2014年5月1日

初级完成 (实际的)

2017年2月1日

研究完成 (实际的)

2017年2月1日

研究注册日期

首次提交

2014年9月12日

首先提交符合 QC 标准的

2014年9月19日

首次发布 (估计)

2014年9月22日

研究记录更新

最后更新发布 (实际的)

2017年6月19日

上次提交的符合 QC 标准的更新

2017年6月15日

最后验证

2017年6月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅